



**THE FOUNDATION  
FOR SECURE  
MARKETS**

#51024

**Date:** September 14, 2022

**Subject:** Caladrius Biosciences, Inc. – Reverse Split and Name/Symbol/CUSIP Change  
Option Symbol: CLBS  
New Symbol: LSTA1  
Date: 09/15/2022

Caladrius Biosciences, Inc. (CLBS) has announced a 1-for-15 reverse stock split and a name, symbol, and CUSIP change. As a result of the reverse stock split and underlying changes, each CLBS Common Share will be converted into the right to receive approximately 0.066667 (New) Lisata Therapeutics, Inc. (LSTA) Common Shares. The reverse stock split and underlying changes will become effective before the market open on September 15, 2022. Cash will be paid in lieu of fractional LSTA shares.

**Contract Adjustment**

**Effective Date:** September 15, 2022

**Option Symbol:** CLBS changes to LSTA1

**Contract  
Multiplier:** 1

**Strike Divisor:** 1

**New Multiplier:** 100 (e.g., for premium or strike dollar extensions 1.00 will equal \$100)

**New Deliverable  
Per Contract:** 1) 6 (New) Lisata Therapeutics, Inc. (LSTA) Common Shares  
2) Cash in lieu of approximately 0.6667 fractional LSTA Shares

Note: Once determined the cash in lieu of fractional share portion of the option deliverable remains fixed and does not vary with price changes of any security.

**CUSIP:** LSTA (New): 128058302

**Pricing**

Until the cash in lieu amount is determined, the underlying price for LSTA1 will be determined as follows:

$$\text{LSTA1} = 0.066667 (\text{LSTA})$$

## **Delayed Settlement**

The LSTA component of the LSTA1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash portion of the LSTA1 deliverable until the cash in lieu of fractional LSTA Shares is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

## **Disclaimer**

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, please email the Investor Education team at [options@theocc.com](mailto:options@theocc.com). Clearing Member Firms of OCC may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email [memberservices@theocc.com](mailto:memberservices@theocc.com).